Journal
PSYCHIATRY RESEARCH
Volume 198, Issue 1, Pages 112-115Publisher
ELSEVIER IRELAND LTD
DOI: 10.1016/j.psychres.2011.12.034
Keywords
Pharmacogenetics; Anxiety disorders; Depression; Treatment response
Categories
Funding
- US Public Health Research Grants [MH065963, K08MH080372]
- Euthymics Biosience, Inc.
- NIMH
- Pamlab
- Pfizer, Inc.
Ask authors/readers for more resources
Antidepressant drugs are the preferred choice for the treatment of generalized anxiety disorder (GAD). However, the choice of pharmacotherapy is determined on a trial-and-error basis, as the underlying mechanisms of treatment response are unknown. We examined whether the COMT gene, which has been known to play a role in antidepressant treatment response in major depressive disorder (MDD), has a pharmacogenetic effect in antidepressant treatment response in GAD. In our study, 156 patients diagnosed with GAD received venlafaxine XR treatment as part of an 18-month relapse prevention study. Genotypes were obtained for the COMT functional variant rs4680 (Va1158Met) for all patients; however, pharmacogenetic analysis was only conducted for the European American population (n=112). We found no significant association between our primary Hamilton Anxiety Scale outcome measure and rs4680. However, we did find a nominally significant allelic association between this variant and a secondary treatment outcome measure (CGI-I) in our European American population (n=112). Furthermore, we show a slight dominant effect of the A-allele with the CGI-I measure in the European American population indicating a possible pharmacogenetic role of rs4680 in antidepressant treatment outcome in GAD. Further studies in a larger population are needed to confirm this effect. (C) 2011 Published by Elsevier Ireland Ltd.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available